<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02780297</url>
  </required_header>
  <id_info>
    <org_study_id>16-000494</org_study_id>
    <nct_id>NCT02780297</nct_id>
  </id_info>
  <brief_title>Prospective Research Rare Kidney Stones (ProRKS)</brief_title>
  <acronym>ProRKS</acronym>
  <official_title>Prospective Research Rare Kidney Stones (ProRKS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the natural history of the hereditary forms of
      nephrolithiasis and chronic kidney disease (CKD), primary hyperoxaluria (PH), cystinuria,
      Dent disease and adenine phosphoribosyltransferase deficiency (APRTd) and acquired enteric
      hyperoxaluria (EH). The investigator will measure blood and urinary markers of inflammation
      and determine relationship to the disease course. Cross-comparisons among the disorders will
      allow us to better evaluate mechanisms of renal dysfunction in these disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe, hereditary forms of nephrolithiasis cause marked excretion of insoluble minerals
      important in stone formation, including primary hyperoxaluria, cystinuria, Dent disease, and
      adenine phosphoribosyltransferase deficiency (APRTd). Patients with these disorders
      experience recurring stones from childhood and are at high risk for chronic kidney disease
      caused by crystal nephropathy. Enteric hyperoxaluria is an acquired disease characterized by
      hyperoxaluria and calcium oxalate crystal nephropathy associated with chronic kidney disease,
      and in that respect similar to the inherited stone diseases. The investigators will collect
      longitudinal data of individual patients in order to provide clues about potentially
      modifiable factors that influence disease severity and identify factors leading to kidney
      injury. the investigator will measure blood and urinary markers of inflammation and determine
      relationship to the disease course. Cross-comparisons among the disorders will allow to
      better evaluate mechanisms of renal dysfunction in these diseases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>inflammatory blood and urinary biomarkers</measure>
    <time_frame>Annually for 5 years</time_frame>
    <description>Statistically significant changes (increase or decrease) in inflammatory urinary biomarkers compared to reference values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Longitudinal changes in eGFR</measure>
    <time_frame>Annually for 5 years</time_frame>
    <description>changes in eGFR during the 5 years</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Development of new onset CKD</measure>
    <time_frame>Annually for 5 years</time_frame>
    <description>Development of new onset CKD stage 4 (eGFR&lt;30) or stage 5 (eGFR&lt;15)</description>
  </other_outcome>
  <other_outcome>
    <measure>Lithogenic substances in the urine</measure>
    <time_frame>Annually for 5 years</time_frame>
    <description>Quantity of change in the substance in the urine</description>
  </other_outcome>
  <other_outcome>
    <measure>Protein in the urine</measure>
    <time_frame>Annually for 5 years</time_frame>
    <description>change in protein in the urine</description>
  </other_outcome>
  <other_outcome>
    <measure>Stone events</measure>
    <time_frame>Annually for 5 years</time_frame>
    <description>change in number of stone events</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Annually for 5 years</time_frame>
    <description>change in the quality of life score</description>
  </other_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Hyperoxaluria</condition>
  <condition>Cystinuria</condition>
  <condition>Dent Disease</condition>
  <condition>Lowe Syndrome</condition>
  <condition>Adenine Phosphoribosyltransferase Deficiency</condition>
  <arm_group>
    <arm_group_label>Primary Hyperoxaluria Patients</arm_group_label>
    <description>Patients with confirmed diagnosis of Primary Hyperoxaluria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dent Disease Patients</arm_group_label>
    <description>Patients with confirmed diagnosis of Dent Disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cystinuria Patients</arm_group_label>
    <description>Patients with confirmed diagnosis of Cystinuria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APRT deficiency Patients</arm_group_label>
    <description>Patients with confirmed diagnosis of adenine phosphoribosyltransferase deficiency (APRTd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lowe Syndrome or Dent 2 patients</arm_group_label>
    <description>Patients with confirmed diagnosis of Lowe Syndrome or Dent 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dent 1 carriers</arm_group_label>
    <description>Patients with confirmed diagnosis of Dent 1. Dent 1 carriers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enteric Hyperoxaluria Patients</arm_group_label>
    <description>Patients with confirmed diagnosis enteric hyperoxaluria.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with Primary Hyperoxaluria, Dent Disease, Cystinuria and APRT Deficiency, Lowe
        syndrome, Dent Disease Carriers and Enteric Hyperoxaluria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of primary hyperoxaluria

          2. Diagnosis of enteric hyperoxaluria

          3. Diagnosis of Dent Disease

          4. Diagnosis of Cystinuria

          5. Diagnosis of adenine phosphoribosyltransferase deficiency (APRTd)

          6. Diagnosis of Lowe Syndrome

          7. Diagnosis of Dent Disease Carrier

        Exclusion Criteria:

          1. Prior renal failure

          2. History of liver and/or kidney transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Lieske, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barb Seide</last_name>
    <phone>800-270-4637</phone>
    <email>RareKidneyStones@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Olson, RN</last_name>
    <phone>800-270-4637</phone>
    <email>RareKidneyStones@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama @ Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Harvey</last_name>
      <phone>205-996-2613</phone>
      <email>lharvey@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Dean Assimos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arta Palaj</last_name>
      <phone>904-953-3071</phone>
      <email>palaj.arta@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ivan Porter, MD</last_name>
      <email>porter.ivan@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>William Haley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heather Price, MS</last_name>
      <email>hprice@childrensmemorial.org</email>
    </contact>
    <investigator>
      <last_name>Craig Langman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Harvard Medical School</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leslie Spaneas</last_name>
      <phone>617-355-6129</phone>
      <email>leslie.spaneas@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michael Somers, MD</last_name>
      <email>michael.somers@childrens.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michelle Baum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hyperoxaluria Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barb Seide</last_name>
      <phone>800-270-4637</phone>
      <email>hyperoxaluriacenter@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julie B Olson, RN</last_name>
      <phone>800-270-4637</phone>
      <email>hyperoxaluriacenter@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dawn Milliner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank Modersitzki, MPH</last_name>
      <phone>216-686-7500</phone>
      <phone_ext>6379</phone_ext>
      <email>Frank.Modersitzki@nyumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Lada Beara-Lasic, MD</last_name>
      <email>lada.bearalasic@nymc.org</email>
    </contact_backup>
    <investigator>
      <last_name>David Goldfarb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hosptial Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Prasad Devarajan, MD</last_name>
      <phone>515-636-4200</phone>
      <email>prasad.devarajan@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Prasad Decarajan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Taylor Moatz</last_name>
      <phone>267-425-3937</phone>
      <email>moatzt@chop.edu</email>
    </contact>
    <investigator>
      <last_name>Lawrence Copelovitch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hosptial of Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Robinson, MD</last_name>
      <phone>416-813-5082</phone>
      <email>lisa.robinson@sickkids.ca</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Harvey, MD</last_name>
      <phone>416-813-5082</phone>
      <email>Elizabeth.harvey@sickkids.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Elizabeth Harvey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Landspitali Universtiy Hospital</name>
      <address>
        <city>Reykjavik</city>
        <country>Iceland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Inger Agustsdottir, RN</last_name>
      <phone>354-824-5227</phone>
      <email>ingeragu@landspitali.is</email>
    </contact>
    <investigator>
      <last_name>Vidar Edvardsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medica Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yaacov Frishberg, MD</last_name>
      <email>yaacovf@ekmd.huji.ac.il</email>
    </contact>
    <investigator>
      <last_name>Yaacov Frishberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Iceland</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>May 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2016</study_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>John Lieske</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>primary hyperoxaluria</keyword>
  <keyword>Dent Disease</keyword>
  <keyword>enteric hyperoxaluria</keyword>
  <keyword>cystinuria</keyword>
  <keyword>Lowe Syndrome</keyword>
  <keyword>Adenine phosphoribosyltransferase deficiency</keyword>
  <keyword>PH</keyword>
  <keyword>APRTd</keyword>
  <keyword>APRT</keyword>
  <keyword>hyperoxaluria</keyword>
  <keyword>oxalate</keyword>
  <keyword>oxalosis</keyword>
  <keyword>PH type 1</keyword>
  <keyword>PH type 2</keyword>
  <keyword>PH type 3</keyword>
  <keyword>Dents</keyword>
  <keyword>Dent</keyword>
  <keyword>Dent 1</keyword>
  <keyword>Dent 2</keyword>
  <keyword>APRT deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Cystinuria</mesh_term>
    <mesh_term>Dent Disease</mesh_term>
    <mesh_term>Oculocerebrorenal Syndrome</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

